Bio-Techne Corporation has reported its financial results for the fiscal year ending June 30, 2025. The company achieved a 5% increase in consolidated net sales, reaching $1.2 billion compared to fiscal 2024. This growth was primarily attributed to strong commercial execution in the Protein Sciences segment, with organic growth also at 5%. However, consolidated net earnings experienced a significant decrease of 56% from the previous year. This decline was influenced by a non-recurring loss on an arbitration award, asset impairment of those held-for-sale, and restructuring-related charges. Non-GAAP adjusted consolidated net earnings before taxes were reported at $98.5 million, a decrease from $185.7 million in fiscal 2024. The company identified several adjustments impacting earnings, including costs recognized upon the sale of acquired inventory and amortization of intangibles. Bio-Techne develops and sells life science reagents, instruments, and services worldwide, playing a key role in scientific investigations and clinical diagnostics.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.